Mantle Cell Lymphoma Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Eli Lilly and Company, Novalgen, Hutchison Medipharma

The Key Mantle Cell Lymphoma Companies in the market include - Bristol Myers Squibb, Eli Lilly, Kite Pharma, BeOne, Roche, Merck, Iksuda Therapeutics, NovalGen, PharmaEngine, Jiangsu Hansoh Pharmaceutical, Galapagos NV, Miltenyi Biomedicine, Roche, Celgene, The Lymphoma Academic Research Org, Loxo Oncology, Janssen R&D, BeiGene, Novartis, Fondazione Italiana Linfomi - ETS, PrECOG, LLC, Acerta Pharma, and others.

 

The Mantle Cell Lymphoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mantle Cell Lymphoma pipeline products will significantly revolutionize the Mantle Cell Lymphoma market dynamics.

 

DelveInsight’s “Mantle Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Mantle Cell Lymphoma, historical and forecasted epidemiology as well as the Mantle Cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Mantle Cell Lymphoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Mantle Cell Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Mantle Cell Lymphoma Market Insights

 

Some of the key facts of the Mantle Cell Lymphoma Market Report:

• The Mantle Cell Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In November 2025, The FDA granted priority review to the new drug application (NDA) for sonrotoclax (BGB-11417) aimed at treating adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received a BTK inhibitor. The NDA is supported by results from the Phase 1/2 BGB-11417-201 trial (NCT05471843), which met its primary endpoint of overall response rate (ORR) assessed by an independent review committee (IRC) and demonstrated clinically meaningful responses in 125 adult patients with relapsed/refractory MCL previously treated with a BTK inhibitor.

• In November 2025, The European Commission has authorized lisocabtagene maraleucel (liso-cel; Breyanzi) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have undergone at least two prior systemic therapies, including a Bruton’s tyrosine kinase (BTK) inhibitor, according to a press release from Bristol Myers Squibb.

• In November 2025, AstraZeneca has launched a Phase II study in Spain to assess the safety and effectiveness of combining acalabrutinib with R-CHOP as a first-line treatment for patients with mantle cell lymphoma (MCL).

• In November 2025, The H. Lee Moffitt Cancer Center and Research Institute has initiated a Phase II clinical study for relapsed or refractory mantle cell lymphoma (R/R MCL) patients who are eligible to receive standard-of-care CD19 CAR T-cell therapy using brexucabtagene autoleucel (brexu-cel).

• In June 2025, The FDA has granted approval for the tablet form of zanubrutinib for treating B-cell cancers, including Mantle Cell Lymphoma, in patients who have undergone at least one previous therapy.

• In May 2025, According to results from the phase 2 ECOG-ACRIN E1411 trial (NCT01415752), adding bortezomib (Velcade) to bendamustine and rituximab (Rituxan; BR) as induction therapy did not lead to improved 2-year progression-free survival (PFS) compared with BR alone in patients with mantle cell lymphoma (MCL). However, Brad S. Kahl, MD, noted that the strong 2-year PFS achieved with BR alone has established a solid foundation for future advancements in MCL treatment.

• In May 2025, Brad Kahl, MD, a professor of medicine, co-chair of the SCC Protocol Review and Monitoring Committee, and director of the Lymphoma Program at Washington University School of Medicine in St. Louis, highlighted the persistent treatment challenges in mantle cell lymphoma (MCL) and stressed the importance of advancing therapeutic options for various patient populations.

• In February 2025, The ROR1-targeted antibody-drug conjugate (ADC) zilovertamab vedotin (MK-2140) demonstrated antitumor efficacy and a tolerable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma (MCL), based on findings from cohort A of the phase 2 waveLINE-006 trial (NCT05458297) presented at the 2024 ASH Annual Meeting.

• In December 2024, Galapagos NV announced additional data from the ongoing Phase I/II ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5101. The results, featured in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, demonstrate strong efficacy and an encouraging safety profile in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Most patients in the study received GLPG5101 as a fresh, fit, stem-like, early memory CD19 CAR T-cell therapy, with a median veinto-vein time of seven days.

• In June 2024, Roche announced the US FDA granted Breakthrough Therapy Designation to Glofitamab for the treatment of Mantle Cell Lymphoma.

• Multiple treatment options are currently approved for Mantle Cell Lymphoma, such as BREYANZI (lisocabtagene maraleucel), JAYPIRCA (pirtobrutinib), TECARTUS (brexucabtagene autoleucel), BRUKINSA, among others.

• Promising upcoming Mantle Cell Lymphoma therapies expected to drive notable progress during the forecast period include COLUMVI (glofitamab) by Roche, BGB-11417 (sonrotoclax) by BeOne, NVG-111 by NovalGen, among other emerging candidates.

• Mantle cell lymphoma (MCL) is an uncommon form of B-cell non-Hodgkin lymphoma (NHL), predominantly affecting men older than 60. It accounts for roughly 5% of all NHL cases and typically begins as a slow-growing disease, though it may progress into a more aggressive form over time.

• Mantle Cell Lymphoma is an uncommon and aggressive subtype of B-cell non-Hodgkin lymphoma, occurring at a rate of roughly one case per 200,000 people each year. Its low prevalence makes early detection difficult and creates hurdles in enrolling patients for clinical studies.

• Mantle Cell Lymphoma represents about 5% of all non-Hodgkin lymphoma cases, categorizing it as a rare subtype. However, it remains clinically important because the disease frequently behaves aggressively and long-term treatment responses are often difficult to sustain.

• The condition displays a notable male predominance, appearing roughly three times more often in men than in women, a trend observed across different regions globally.

• The median age for diagnosis generally ranges from 60 to 70 years, with the majority of patients diagnosed in their late 60s. Mantle Cell Lymphoma primarily affects older adults, and the patient’s age at diagnosis can impact treatment choices and overall prognosis.

• Key Mantle Cell Lymphoma Companies: Bristol Myers Squibb, Eli Lilly, Kite Pharma, BeOne, Roche, Merck, Iksuda Therapeutics, NovalGen, PharmaEngine, Jiangsu Hansoh Pharmaceutical, Galapagos NV, Miltenyi Biomedicine, Roche, Celgene, The Lymphoma Academic Research Org, Loxo Oncology, Janssen R&D, BeiGene, Novartis, Fondazione Italiana Linfomi - ETS, PrECOG, LLC, Acerta Pharma, and others

• Key Mantle Cell Lymphoma Therapies: BREYANZI (lisocabtagene maraleucel), JAYPIRCA (pirtobrutinib), TECARTUS (brexucabtagene autoleucel), Sonrotoclax, COLUMVI (glofitamab), Zilovertamab Vedotin, IKS03, NVG-111, PEP07, LP-168, GLPG5101, Zamtocabtagene autoleucel, Glofitamab, Lenalidomide, Obinutuzumab, Pirtobrutinib, Ibrutinib, BGB-11417, Everolimus, Venetoclax, Ixazomib, Acalabrutinib, and others

 

Mantle Cell Lymphoma Overview

A uncommon form of B-cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL) affects one in 200 000 persons each year. Around 5% of non-Hodgkins lymphomas are MCL. The median age at diagnosis for MCL is between 60 and 70 years old, and men are more likely to develop it (3 to 1).

 

Get a Free sample for the Mantle Cell Lymphoma Market Report:

https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market

 

Mantle Cell Lymphoma Epidemiology

The Mantle Cell Lymphoma epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Mantle Cell Lymphoma Epidemiology Segmentation:

The Mantle Cell Lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Mantle Cell Lymphoma

• Prevalent Cases of Mantle Cell Lymphoma by severity

• Gender-specific Prevalence of Mantle Cell Lymphoma

• Diagnosed Cases of Episodic and Chronic Mantle Cell Lymphoma

 

Download the report to understand which factors are driving Mantle Cell Lymphoma epidemiology trends @ Mantle Cell Lymphoma Epidemiological Insights

 

Mantle Cell Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mantle Cell Lymphoma market or expected to get launched during the study period. The analysis covers Mantle Cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Mantle Cell Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Mantle Cell Lymphoma Therapies and Key Companies

• BREYANZI (lisocabtagene maraleucel): Bristol Myers Squibb

• JAYPIRCA (pirtobrutinib): Eli Lilly

• TECARTUS (brexucabtagene autoleucel): Kite Pharma

• Sonrotoclax: BeOne

• COLUMVI (glofitamab): Roche

• Zilovertamab Vedotin: Merck

• IKS03: Iksuda Therapeutics

• NVG-111: NovalGen

• PEP07: PharmaEngine

• LP-168: Jiangsu Hansoh Pharmaceutical

• GLPG5101: Galapagos NV

• Zamtocabtagene autoleucel: Miltenyi Biomedicine

• Glofitamab: Roche

• Lenalidomide: Celgene

• Obinutuzumab: The Lymphoma Academic Research Org

• Pirtobrutinib: Loxo Oncology

• Ibrutinib: Janssen R&D

• BGB-11417: BeiGene

• Everolimus: Novartis

• Venetoclax: Fondazione Italiana Linfomi - ETS

• Ixazomib: PrECOG, LLC

• Acalabrutinib: Acerta Pharma

 

Discover more about therapies set to grab major Mantle Cell Lymphoma market share @ Mantle Cell Lymphoma Medications

 

Mantle Cell Lymphoma Market Drivers

• Growing prevalence of MCL and increasing diagnosis due to improved screening and awareness.

• Advancements in targeted therapies, including BTK inhibitors, CAR-T cell therapies, and combination regimens.

• Rising adoption of personalized medicine and biomarker-driven treatment approaches.

• Strong R&D pipeline with ongoing clinical trials enhancing treatment options and survival outcomes.

• Favorable regulatory support, including fast-track and orphan drug designations to accelerate approvals.

 

Mantle Cell Lymphoma Market Barriers

• High cost of advanced therapies such as CAR-T and targeted inhibitors, limiting accessibility.

• Limited curative options and high relapse rates despite treatment advancements.

• Small patient population due to the rare nature of the disease, restricting commercial returns.

• Adverse effects associated with systemic therapies impacting treatment compliance.

• Reimbursement challenges in several regions reducing therapy adoption.

• Complexity in treatment sequencing and lack of standardized long-term management strategies.

 

Scope of the Mantle Cell Lymphoma Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Mantle Cell Lymphoma Companies: Bristol Myers Squibb, Eli Lilly, Kite Pharma, BeOne, Roche, Merck, Iksuda Therapeutics, NovalGen, PharmaEngine, Jiangsu Hansoh Pharmaceutical, Galapagos NV, Miltenyi Biomedicine, Roche, Celgene, The Lymphoma Academic Research Org, Loxo Oncology, Janssen R&D, BeiGene, Novartis, Fondazione Italiana Linfomi - ETS, PrECOG, LLC, Acerta Pharma, and others

• Key Mantle Cell Lymphoma Therapies: BREYANZI (lisocabtagene maraleucel), JAYPIRCA (pirtobrutinib), TECARTUS (brexucabtagene autoleucel), Sonrotoclax, COLUMVI (glofitamab), Zilovertamab Vedotin, IKS03, NVG-111, PEP07, LP-168, GLPG5101, Zamtocabtagene autoleucel, Glofitamab, Lenalidomide, Obinutuzumab, Pirtobrutinib, Ibrutinib, BGB-11417, Everolimus, Venetoclax, Ixazomib, Acalabrutinib, and others

• Mantle Cell Lymphoma Therapeutic Assessment: Mantle Cell Lymphoma current marketed and Mantle Cell Lymphoma emerging therapies

• Mantle Cell Lymphoma Market Dynamics: Mantle Cell Lymphoma market drivers and Mantle Cell Lymphoma market barriers

• Mantle Cell Lymphoma Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Mantle Cell Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Mantle Cell Lymphoma Market Access and Reimbursement

 

To know more about Mantle Cell Lymphoma treatment, visit @ Mantle Cell Lymphoma Treatment Landscape

 

Table of Contents

1. Mantle Cell Lymphoma Market Report Introduction

2. Executive Summary for Mantle Cell Lymphoma

3. SWOT analysis of Mantle Cell Lymphoma

4. Mantle Cell Lymphoma Patient Share (%) Overview at a Glance

5. Mantle Cell Lymphoma Market Overview at a Glance

6. Mantle Cell Lymphoma Disease Background and Overview

7. Mantle Cell Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Mantle Cell Lymphoma

9. Mantle Cell Lymphoma Current Treatment and Medical Practices

10. Mantle Cell Lymphoma Unmet Needs

11. Mantle Cell Lymphoma Emerging Therapies

12. Mantle Cell Lymphoma Market Outlook

13. Country-Wise Mantle Cell Lymphoma Market Analysis (2020–2034)

14. Mantle Cell Lymphoma Market Access and Reimbursement of Therapies

15. Mantle Cell Lymphoma Market Drivers

16. Mantle Cell Lymphoma Market Barriers

17. Mantle Cell Lymphoma Appendix

18. Mantle Cell Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Canadian-Made ArthriMED-Plus Powers Active Lifestyles with Natural, Essential Oil Muscle Relief

ArthriMED-Plus, a Quebec-made essential-oil spray, launches a nationwide initiative supporting athletes and active individuals with fast, natural relief for muscle and joint discomfort. The brand promotes clean, convenient recovery for Canadians on the move.

Proudly crafted in Quebec, ArthriMED-Plus offers Canadians a clean, essential-oil-based solution for soothing sore muscles and stiff joints. The brand's new campaign highlights natural recovery for sports, outdoor activities, and busy lifestyles.

As more Canadians embrace active, movement-driven lifestyles, the need for fast, natural recovery products continues to grow. ArthriMED-Plus, a Quebec-made essential-oil spray, is taking center stage with a national initiative designed to support athletes, fitness enthusiasts, and everyday movers seeking relief from muscle and joint discomfort.

Crafted with a blend of premium essential oils—menthol, camphor, eucalyptus, and clove—ArthriMED-Plus delivers an effective, plant-based alternative to heavy synthetic creams and gels. The product has become a popular choice among active adults, gym-goers, outdoor adventurers, and individuals recovering from daily physical strain. Its convenient spray format allows for targeted application without rubbing, making it ideal for post-workout routines, long days at work, and moments when relief is needed quickly.

Natural Support for Muscle Recovery and Everyday Comfort

Whether after an intense training session, a long hike, a demanding workday, or simply the natural stiffness that comes with an active life, Canadians are looking for trustworthy solutions that help them recover faster. ArthriMED-Plus was created to meet that need using a clean, easily absorbed formula that avoids harsh chemicals, artificial fragrances, and greasy residues.

“Our goal has always been to help Canadians move with confidence,” said Michael, CEO at ArthriMED-Plus. “People want natural products that fit their lifestyle. ArthriMED-Plus brings together simplicity, convenience, and real effectiveness—without compromising on safety or quality.”

The spray can be applied several times per day and works quickly without leaving residue on the skin. Because there is no need to massage the product in, it is particularly appreciated by athletes who need quick post-training relief, workers who rely on mobility, and anyone living a fast-paced lifestyle.

Championing a More Natural Approach to Recovery

Today’s consumers are increasingly moving away from synthetic-heavy formulations and turning toward natural wellness alternatives. ArthriMED-Plus has become part of that shift, offering a formula that helps ease tension, soothe discomfort, and support flexibility with ingredients rooted in nature.

“We’re proud to offer a Canadian-made solution that truly aligns with the way people live now,” added Michael. “Whether someone trains competitively, enjoys weekend sports, or simply wants to feel better during day-to-day activities, our product makes recovery simpler and more natural.”

A Quebec Success Story Trusted Since 2010

Founded in 2010, ArthriMED-Plus has grown into a trusted wellness brand known for quality, safety, and consistency. Every bottle is manufactured in Quebec, ensuring high production standards and supporting local employment. The company continues to expand its reach as more Canadians discover natural options for relieving everyday muscle and joint tension.

Practical Formats for Active Lifestyles

ArthriMED-Plus is available in multiple bottle sizes to suit every need—from compact, travel-friendly sprays for gym bags and backpacks, to larger bottles designed for home use or family recovery kits. The easy-spray mechanism makes it a convenient companion for sports, travel, and busy days on the go.

Customers can explore the full product line and order directly from the brand’s website: www.arthrimed-plus.ca

About ArthriMED-Plus

ArthriMED-Plus is a Quebec-based wellness brand specializing in natural essential-oil sprays for temporary relief of muscle aches, joint stiffness, and post-exercise discomfort. The formula supports active lifestyles, athletic recovery, and everyday mobility. Trusted since 2010, ArthriMED-Plus continues to prioritize natural ingredients, local manufacturing, and reliable results.

Media Contact
Company Name: Arthrimed Plus
Contact Person: Michael Zak
Email:Send Email
Country: Canada
Website: https://www.arthrimed-plus.ca/

Affiliate Partners Invited to Promote QuickSnap Pro - A New Productivity Chrome Extension

Join the Quicksnap Pro launch and bank big with this low cost time saver!

QuickSnap Pro introduces a streamlined way for digital marketers and online creators to manage their essential assets with one click. Designed to eliminate the daily friction of searching through scattered files, the extension centralizes affiliate links, templates, prompts, and social content inside a single, intuitive sidebar. With its universal appeal, near-zero learning curve, and proven time-saving impact,

December 5, 2025 - Benjamin Hübner, a long-time affiliate marketing professional with more than 13 years of hands-on experience, will introduce QuickSnap Pro, a new Chrome extension designed to simplify how marketers and online creators store and access their most-used digital assets. The launch will run from December 11 to December 16, 2025, and offers an appealing earning opportunity for Joint Venture (JV) partners looking to promote a broadly useful, high-converting tool.

Digital marketers frequently navigate a growing collection of URLs, scripts, templates, prompts, and reusable content across multiple files and platforms. This scattered workflow often leads to frustration and lost productivity. QuickSnap Pro centralizes these assets inside a single smart, searchable sidebar, enabling users to save content with a right-click and retrieve it instantly.

The tool allows for seamless organization and retrieval of:

• Affiliate links and tracking URLs

• High-performing messages, DMs, and templates

• Hooks, headlines, and CTAs

• AI prompts and reusable ChatGPT instructions

• Social post drafts, scripts, and micro-content

Additional optional features include a lightweight To-Do system, integrated AI content tools, and a personal Content Bank. With its near-zero learning curve, QuickSnap Pro has been designed for daily use, making it highly accessible while supporting strong long-term retention.

JV Partners Can Expect:

• Strong Earnings Potential: Up to $85 USD per customer, with 100% commissions on the Front End (priced from $12.95 to $17.00).

• Launch Contest Incentives: A $500 prize pool for top-performing affiliates.

• Reliable Conversions: The product solves a well-known daily problem—locating frequently used digital assets—backed by a clear, visual demonstration that showcases its speed advantage over traditional workflows.

• High EPCs & Solid User Satisfaction: Developed by an established 13-year industry veteran, the product benefits from predictable performance and dependable customer support.

Affiliates who wish to explore the product, access promotional assets, or participate in the launch will find all necessary materials available on the official JV page.

JV Resources Available:

• JV Signup Link

• QuickSnap Pro Demo Video

“QuickSnap Pro was created from a real, everyday challenge that affects nearly everyone working online,” said Benjamin Hübner, creator of the software. “The extension removes friction, saves time, and helps users stay organized. It also presents a valuable opportunity for JV partners seeking a product that is easy to promote and resonates immediately with a broad audience.”

About QuickSnap Pro

QuickSnap Pro is a Chrome extension designed to help online professionals manage digital assets with speed and simplicity. By allowing users to save, categorize, and access important links, templates, prompts, and other frequently used items from a single sidebar, it reduces workflow friction and enhances productivity. The tool was developed by Benjamin Hübner, a 13-year affiliate marketing veteran known for creating practical, conversion-focused digital solutions.

Video Link: https://www.youtube.com/embed/ApVAOY0wHF0

Media Contact
Company Name: QuickprofitformularX
Contact Person: Benjamin Hübner
Email:Send Email
Phone: 4915782342523
Address:NORTH BRIDGE ROAD #B1-35 HIGH STREET CENTRE
City: Singapore, 179094
Country: Singapore
Website: quickprofitformulax.com

Creddley Launches New Online Loan Service for Borrowers With Bad Credit, Featuring No Hard Credit Checks

Joshua Adam, CEO & Founder of Creddley, which provides fast online loan options for borrowers with bad or limited credit and no hard credit checks.

Creddley has launched a new online loan-options service for borrowers with bad or limited credit, offering fast approvals, soft credit checks only, and loan offers from $200 to $5,000+. The platform supports same-day funding in some cases, charges no fees to apply, and features simple requirements. Creddley aims to provide a straightforward, mobile-friendly way for users to review potential loan options without harming their credit score.

Spokane, WA - Creddley today announced the launch of its online loan-options service built to help borrowers with bad or limited credit history access personal loan offers from $200 to $5,000+. The platform delivers a fast, mobile-ready application process that uses only a soft credit inquiry, giving consumers a way to explore loan options without impacting their credit score. As interest rates trend downward in 2025 and digital borrowing demand increases,

Many applicants continue to face high decline rates at traditional banks, especially those with subprime credit. Rising online search demand for new lending alternatives in 2025 highlights the shift toward quicker digital options. Creddley addresses this trend with a no-fee, low-friction application designed for speed and clarity.

Online Loan Options for Bad Credit Borrowers Seeking $200–$5,000

Creddley’s new service includes features built around borrower accessibility and quick decision-making:

• Loan options from $200–$5,000+
• No fees to apply
• No hard credit check — soft pull only
• Decisions often available within minutes
• Same-day funding available after approval (varies by lender and state)
• APRs typically 5.99%–35.99% depending on credit profile
• Personal and installment loan types supported
• Available in 45 U.S. states

Quick Online Loan Process With Soft Credit Check Only

Creddley’s digital request system is structured for efficiency:

1. User completes a short online application
2. A soft credit pull is performed (no score impact)
3. System displays potential loan offers
4. Applicant reviews and accepts an offer if suitable
5. Funding may be delivered as soon as the same day, depending on lender and banking partner

Addressing Growing Demand for Fast Loans and Bad Credit Alternatives in 2025

Borrowers with low credit scores frequently face obstacles when seeking emergency or short-term funds. Expenses such as medical bills, car repairs, and utility gaps often require immediate attention, yet many traditional lenders still reject applicants with imperfect credit histories. Meanwhile, consumer preference continues shifting toward fast online loan solutions that eliminate paperwork and waiting periods.

Creddley’s launch meets this evolving demand by offering a streamlined, transparent process tailored to borrowers who need quick access to loan options without undergoing a hard credit check.

Founder Highlights Fast Decisions

“Most people reaching out to us aren’t planning months ahead — they’re dealing with something today,” Adam said. “That’s why Creddley focuses on fast decisions and, in some cases, same-day deposits from participating lenders. The goal is to cut out delays when time matters most.”

Who Benefits Most From Creddley’s Bad Credit Loan Platform

The platform is designed for:

• Borrowers with bad credit or limited credit history
• People searching for new loan companies in 2025
• Individuals needing fast loans from $200–$5,000
• Consumers seeking alternatives to traditional bank loan denials
• Users facing immediate expenses such as medical or car repair bills
• Applicants who prefer mobile, digital-first loan tools

Borrowers Who Benefit Most From Creddley’s Online Loan Tool

Creddley’s service is designed to support a wide range of borrowers, particularly those who face barriers in traditional lending environments. This includes bad credit borrowers, individuals who need $200–$5,000 quickly, and users who prefer fast, digital alternatives to bank applications. The platform is also useful for people facing emergency or short-gap expenses such as medical bills, car repairs, or overdue utilities. Consumers seeking modern, mobile-friendly tools to compare loan options will also find Creddley’s process accessible and straightforward.

Launch Aligns With Broader Trends in Digital Lending

The introduction of Creddley comes at a time when subprime borrowers continue to experience high bank decline rates, contributing to a growing demand for more flexible financial solutions. Interest in digital loan tools has risen significantly as consumers seek faster, less burdensome paths to evaluate borrowing options. The year 2025 has also seen an increased shift toward flexible, mobile-first lending platforms, making Creddley’s launch particularly timely.

Important Disclosures and Limitations

Creddley operates solely as an online loan-options service and is not a lender. Approval for any loan offer is not guaranteed.

Loan terms, APRs, amounts, and funding timelines vary by lender and by state. Service availability is limited and not offered in all U.S. states.

How to Apply

Applicants can begin by submitting a request at www.creddley.com, where the online form typically takes only a few minutes to complete. To be considered by participating lenders, users should meet several basic requirements: be 18 or older, a U.S. citizen or permanent resident, have an active checking account, maintain at least 90 days of employment, and earn $1,000 or more in monthly income. These criteria help determine initial eligibility, though final loan decisions and terms vary by lender and state.

About Creddley

Creddley is an online loan-options service that helps individuals — including those with bad credit — access personal loan offers ranging from $200 to $5,000+. The service is designed around what borrowers value most today: quick approval reviews, no fees to apply, simple eligibility requirements, and the possibility of same-day deposits when approved by a participating lender. Founded in 2025 and based in Spokane, WA, Creddley provides a straightforward digital pathway for users to compare loan options without undergoing a hard credit check.

Media Contact
Company Name: Creddley
Contact Person: Joshua Adam
Email:Send Email
City: Spokane
State: WA
Country: United States
Website: https://www.creddley.com/

Schizophrenia Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharma, Minerva Neuro

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Schizophrenia pipeline constitutes 55+ key companies continuously working towards developing 60+ Schizophrenia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Schizophrenia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Schizophrenia Market.

 

The Schizophrenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Schizophrenia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Schizophrenia treatment therapies with a considerable amount of success over the years.

• Schizophrenia companies working in the treatment market are Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others, are developing therapies for the Schizophrenia treatment

• Emerging Schizophrenia therapies in the different phases of clinical trials are- REXULTI/RXULTI, CAPLYTA, LONASEN, ABILIFY MYCITE, RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others are expected to have a significant impact on the Schizophrenia market in the coming years.

• In September 2025, The FDA approved an injectable extended-release risperidone suspension from Amneal Pharmaceuticals, referencing Janssen Biotech’s Risperdal Consta, for the treatment of schizophrenia. This extended-release formulation is now available in 12.5 mg, 25 mg, 37.5 mg, and 50 mg vials.

• In August 2025, BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company leveraging artificial intelligence to develop innovative neuroscience treatments, announced that it received favorable feedback from the FDA following a pre-sNDA meeting. Based on this guidance, the company believes its planned sNDA submission package will be adequate to support the filing, which is still on schedule for the first quarter of 2026.

• In May 2025, Neurocrine Biosciences initiated a Phase III registrational program to evaluate the investigational oral muscarinic M4 selective orthosteric agonist, NBI-1117568, for treating schizophrenia in adults. This double-blind, placebo-controlled trial will assess the therapy’s safety, tolerability, and efficacy in patients experiencing an acute exacerbation or relapse of schizophrenia symptoms. Approximately 280 participants are expected to be enrolled. The primary endpoint is the reduction in the Positive and Negative Syndrome Scale (PANSS) from baseline, with improvement in the Clinical Global Impression of Severity (CGI-S) scale as a key secondary endpoint.

• In May 2025, Vanda Pharmaceuticals reported that the FDA has accepted the New Drug Application (NDA) for Bysanti™ (milsaperidone) without raising any review concerns. The agency has scheduled February 21, 2026, as the decision date. Milsaperidone, a novel chemical entity and active metabolite of iloperidone, has demonstrated dose-dependent bioequivalence in clinical studies.

• In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral film therapy for schizophrenia. Formulated with aripiprazole, it dissolves in the mouth, improving adherence without requiring water.

• In March 2025, Vanda Pharmaceuticals Inc. has submitted a New Drug Application (NDA) to the FDA seeking marketing approval for Bysanti™ (milsaperidone) as a treatment for acute bipolar I disorder and schizophrenia, backed by several clinical studies demonstrating its safety and efficacy.

• In March 2025, LB Pharmaceuticals Inc., a clinical-stage biopharma company focused on developing innovative treatments for neuropsychiatric disorders such as schizophrenia, has shared new positive findings from its NOVA1 Phase 2 clinical trial of LB-102 in patients experiencing acute schizophrenia exacerbations. The data was presented at the 2025 Annual Congress of the Schizophrenia International Research Society (SIRS), currently taking place in Chicago.

• In February 2025, The September 2024 approval of xanomeline-trospium chloride (Cobenfy; Bristol Myers Squibb) marks the first novel schizophrenia treatment in 70 years. While some experts have welcomed the milestone, others remain cautious. Unlike traditional antipsychotics that target dopamine D2 receptors, this therapy works through muscarinic acetylcholine receptors, offering a distinct mechanism of action.

• In January 2025, German pharmaceutical leader Boehringer Ingelheim revealed that its investigational drug iclepertin, intended to treat cognitive impairment in schizophrenia patients, did not meet any primary or secondary endpoints across three Phase III trials. The CONNEX program results showed no significant cognitive or functional improvements over placebo after six months. However, the company noted that iclepertin maintained a favorable safety profile.

• In January 2025, Segal Trials, a private clinical research organization focused on acute schizophrenia and other psychiatric conditions, has shared its enrollment performance data from its involvement in NOVA—a Phase 2 dose-finding study in adults with acute schizophrenia assessing LB-102, a once-daily oral small molecule and potential first-in-class benzamide antipsychotic.

 

Schizophrenia Overview

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. It is characterized by symptoms such as hallucinations, delusions, disorganized thinking, and impaired social or occupational functioning. The exact cause is unknown, but a combination of genetic, brain chemistry, and environmental factors is believed to contribute. Schizophrenia typically emerges in late adolescence or early adulthood and requires long-term treatment, often combining antipsychotic medications and psychosocial therapies, to manage symptoms and improve quality of life.

 

Get a Free Sample PDF Report to know more about Schizophrenia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight

 

Emerging Schizophrenia Drugs Under Different Phases of Clinical Development Include:

• REXULTI/RXULTI: Lundbeck

• CAPLYTA: Intra-cellular Therapies

• LONASEN: Sumitomo Pharma

• ABILIFY MYCITE: Otsuka Pharma

• RP5063 (brilaroxazine): Reviva Pharmaceuticals

• MIN-101 (roluperidone): Minerva Neurosciences

• KarXT (xanomeline-trospium): Karuna Therapeutics

• NUPLAZID (pimavanserin): Acadia Pharmaceuticals

• ICELPERTIN (BI-425809): Boehringer Ingelheim

• SEP-363856 (ulotaront): Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical

• OKEDI (risperidone ISM): Laboratorios Farmacéuticos Rovi

• LYN-005: Lyndra Therapeutics

• NW-3509/NW-3509A (evenamide): Newron Pharmaceuticals

• CVL-231 (emraclidine): Cerevel Therapeutics

• Seroquel Sustained Release: AstraZeneca

• Intramuscular Olanzapine Depot: Eli Lilly and Company

• Xanomeline and Trospium Chloride Capsules: Karuna Therapeutics

• NBI-1117568: Neurocrine Biosciences

 

Schizophrenia Emerging Therapy Assessment:

Olanzapine LAI (TEV-’749): Teva Pharmaceutical Industries/Royalty Pharma/MedinCell

TEV-’749 is an investigational, once-monthly, long-acting subcutaneous injection of the second-generation antipsychotic olanzapine, which has not been approved by any regulatory authority for any use, and its safety and efficacy remain unestablished. Teva’s schizophrenia portfolio has gained momentum with TEV-’749 (olanzapine), a once-monthly subcutaneous long-acting injectable.

• In 2024–2025, results from the Phase III SOLARIS trial showed that TEV-’749 met its primary endpoint by significantly improving PANSS scores at 8 weeks, along with demonstrating positive effects on social functioning and quality of life.

• By March 2025,over 92% of patients reported satisfaction with the initiation regimen and dosing schedule.

• Teva entered a funding agreement with Royalty Pharma in November 2023, securing up to USD 125 million to advance TEV-’749's clinical development.

 

Ulotaront (SEP-363856): SumitomoPharma/OtsukaPharmaceuticals

Ulotaront (SEP-363856) is a trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, which is a small molecule oral agent that does not bind to dopamine D2 or serotonin 5-HT2A receptors. Ulotaront is being jointly developed and commercialized as part of a collaboration between Sumitomo Pharma, its US subsidiary Sumitomo Pharma America (SMPA), and Otsuka. SMPA discovered ulotaront in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms. Currently, Ulotaront is being investigated in late-stage development for schizophrenia and Generalized Anxiety Disorder (GAD) in Japan, while adjunctive major depressive disorder, schizophrenia, and GAD in the US.

 

Brilaroxazine (RP-5063): Reviva Pharmaceuticals

Brilaroxazine (RP-5063) is a new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and other psychiatric disorders. RP-5063 is a multimodal modulator of the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT7 receptors and D2, D3, and D4 dopamine receptors in clinical development for multiple neuropsychiatric indications,. Additionally, the drug candidate is also being investigated for bipolar disorder, major depressive disorder (MDD), attention deficit/hyperactivity disorder (ADHD), and inflammatory diseases (including pulmonary arterial hypertension, idiopathic pulmonary fibrosis, and psoriasis). The Phase III RECOVER-2 trial of brilaroxazine in schizophrenia is expected to begin in mid-2025, pending additional financing, with topline results anticipated in Q3 2026 with potential NDA submission in Q4 2026.

 

Roluperidone (MIN-101/MT-210):Minerva Neurosciences/Mitsubishi Tanabe Pharma

Minerva Neurosciences is developing roluperidone (MIN-101) to treat negative symptoms of schizophrenia that persist chronically for a lifetime and can contribute to poor quality of life and functional outcomes. The drug can block serotonin and sigma receptors, two receptors in the brain that are involved in regulating mood, cognition, sleep, and anxiety. The company holds the license to roluperidone from Mitsubishi Tanabe Pharma Corporation with the rights to develop, sell, and import roluperidone (MT-210) globally. The drug candidate has completed Phase III (US) for negative symptoms of schizophrenia.

 

Schizophrenia Route of Administration

Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

 

Schizophrenia Molecule Type

Schizophrenia Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

 

Schizophrenia Pipeline Therapeutics Assessment

• Schizophrenia Assessment by Product Type

• Schizophrenia By Stage and Product Type

• Schizophrenia Assessment by Route of Administration

• Schizophrenia By Stage and Route of Administration

• Schizophrenia Assessment by Molecule Type

• Schizophrenia by Stage and Molecule Type

 

DelveInsight's Schizophrenia Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Further Schizophrenia product details are provided in the report. Download the Schizophrenia pipeline report to learn more about the emerging Schizophrenia therapies

 

Some of the key companies in the Schizophrenia Therapeutics Market include:

Key companies developing therapies for Schizophrenia are - Otsuka Pharmaceutical Co., Ltd., AstraZeneca, Sumitomo Dainippon Pharma, Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly and Company, Alkermes Plc, Vanda Pharmaceuticals Inc., and others.

 

Schizophrenia Pipeline Analysis:

The Schizophrenia pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Schizophrenia with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Schizophrenia Treatment.

• Schizophrenia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Schizophrenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Schizophrenia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Schizophrenia drugs and therapies

 

Schizophrenia Pipeline Market Drivers

• Increasing popularity among individuals for long-acting injectable (LAI) antipsychotics are key factors driving growth of the global schizophrenia drugs market.

 

Schizophrenia Pipeline Market Barriers

• WHO’s Comprehensive Mental Health Action Plan 2013- 2030 will further enhance the awareness about mental health by ensuring 100 million more people have access to quality and affordable care for mental health conditions.

 

Scope of Schizophrenia Pipeline Drug Insight

• Coverage: Global

• Key Schizophrenia Companies: Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others

• Key Schizophrenia Therapies: REXULTI/RXULTI, CAPLYTA, LONASEN, ABILIFY MYCITE, RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others

• Schizophrenia Therapeutic Assessment: Schizophrenia current marketed and Schizophrenia emerging therapies

• Schizophrenia Market Dynamics: Schizophrenia market drivers and Schizophrenia market barriers

 

Request for Sample PDF Report for Schizophrenia Pipeline Assessment and clinical trials

 

Table of Contents

1. Schizophrenia Report Introduction

2. Schizophrenia Executive Summary

3. Schizophrenia Overview

4. Schizophrenia- Analytical Perspective In-depth Commercial Assessment

5. Schizophrenia Pipeline Therapeutics

6. Schizophrenia Late Stage Products (Phase II/III)

7. Schizophrenia Mid Stage Products (Phase II)

8. Schizophrenia Early Stage Products (Phase I)

9. Schizophrenia Preclinical Stage Products

10. Schizophrenia Therapeutics Assessment

11. Schizophrenia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Schizophrenia Key Companies

14. Schizophrenia Key Products

15. Schizophrenia Unmet Needs

16 . Schizophrenia Market Drivers and Barriers

17. Schizophrenia Future Perspectives and Conclusion

18. Schizophrenia Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Pancreatic Ductal Adenocarcinoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Elicio Therapeutics, Cend Therapeutics, Silenseed, Amplia

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pancreatic Ductal Adenocarcinoma pipeline constitutes 80+ key companies continuously working towards developing 80+ Pancreatic Ductal Adenocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic Ductal Adenocarcinoma Market.

 

The Pancreatic Ductal Adenocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Pancreatic Ductal Adenocarcinoma treatment therapies with a considerable amount of success over the years.

• Pancreatic Ductal Adenocarcinoma companies working in the treatment market are Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, and others, are developing therapies for the Pancreatic Ductal Adenocarcinoma treatment

• Emerging Pancreatic Ductal Adenocarcinoma therapies in the different phases of clinical trials are- DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, and others are expected to have a significant impact on the Pancreatic Ductal Adenocarcinoma market in the coming years.

• In May 2025, The FDA has awarded fast track designation to EBC-129 as a potential treatment for patients with pancreatic ductal adenocarcinoma. This antibody-drug conjugate (ADC) targets a tumor-specific N256-glycosylation site present on CEACAM5 and CEACAM6, proteins involved in tumor development, migration, and metastasis. The therapy’s safety and tolerability are being evaluated both as a monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors.

• In January 2025, Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative treatments for advanced solid tumors and serious diseases, along with WARPNINE Incorporated, Western Australia’s first not-for-profit clinical research organization specializing in pancreatic, gastrointestinal, and rare cancers, has announced promising preliminary results from the Phase 1b/2a iLSTA trial (ACTRN12623000223639). The trial evaluates certepetide (formerly LSTA1), Lisata's proprietary investigational iRGD cyclic peptide, in combination with standard-of-care chemotherapy and immunotherapy as a first-line treatment for locally advanced, non-resectable pancreatic ductal adenocarcinoma (PDAC).

• In October 2024, Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced that the first patient has been dosed in RASolute 302, a Phase 3 registrational trial evaluating RMC-6236, a RAS(ON) multi-selective inhibitor, for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

• In May 2024, Hong Kong-based biopharmaceutical company Hutchmed has initiated a Phase II/III clinical trial in China to evaluate surufatinib in combination with other drugs as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). The treatment regimen includes surufatinib, camrelizumab from Jiangsu Hengrui Pharmaceuticals, nab-paclitaxel, and gemcitabine.

• In January 2024, Jacobio Pharmaceuticals' pancreatic cancer candidate, glecirasib, has demonstrated improved safety and efficacy compared to previous studies in a Phase I/II trial involving patients with pancreatic cancer and other solid tumors. The Phase I/II monotherapy global study of glecirasib reported a confirmed objective response rate (cORR) of 48% and a disease control rate (DCR) of 90%. These study results will support the submission of a new drug application (NDA) for pancreatic cancer.

 

Pancreatic Ductal Adenocarcinoma Overview

Pancreatic Ductal Adenocarcinoma (PDAC) is the most common type of pancreatic cancer, arising from the ductal cells of the pancreas. It is highly aggressive, often diagnosed at an advanced stage, and associated with poor prognosis. Risk factors include age, smoking, chronic pancreatitis, diabetes, and genetic predisposition. Symptoms may include abdominal pain, jaundice, weight loss, and digestive issues, but early-stage disease is frequently asymptomatic. Treatment typically involves a combination of surgery, chemotherapy, radiation, and emerging targeted or immunotherapies, though the overall survival rate remains low due to late diagnosis and rapid disease progression.

 

Get a Free Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight

 

Emerging Pancreatic Ductal Adenocarcinoma Drugs Under Different Phases of Clinical Development Include:

• DCC-3116: Deciphera Pharmaceuticals

• RMC-6236: Revolution Medicines

• SX-682: Syntrix Biosystems

• AMP 945: Amplia Therapeutics

• ZB131: ZielBio

• CEND-1: Cend Therapeutics Inc

• Onvansertib: Cardiff Oncology

• YH003: Eucure Biopharma

• KN046: Jiangsu Alphamab Biopharmaceuticals

 

Pancreatic Ductal Adenocarcinoma Route of Administration

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Intravenous

• Subcutaneous

 

Pancreatic Ductal Adenocarcinoma Molecule Type

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types, such as

• Small molecule

• Cell Therapy

• Peptides

• Polymer

• Small molecule

• Gene therapy

 

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment

• Pancreatic Ductal Adenocarcinoma Assessment by Product Type

• Pancreatic Ductal Adenocarcinoma By Stage and Product Type

• Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration

• Pancreatic Ductal Adenocarcinoma By Stage and Route of Administration

• Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type

• Pancreatic Ductal Adenocarcinoma by Stage and Molecule Type

 

DelveInsight's Pancreatic Ductal Adenocarcinoma Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Further Pancreatic Ductal Adenocarcinoma product details are provided in the report. Download the Pancreatic Ductal Adenocarcinoma pipeline report to learn more about the emerging Pancreatic Ductal Adenocarcinoma therapies

 

Some of the key companies in the Pancreatic Ductal Adenocarcinoma Therapeutics Market include:

Key companies developing therapies for Pancreatic Ductal Adenocarcinoma are - Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.

 

Pancreatic Ductal Adenocarcinoma Pipeline Analysis:

The Pancreatic Ductal Adenocarcinoma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Ductal Adenocarcinoma Treatment.

• Pancreatic Ductal Adenocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Pancreatic Ductal Adenocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Ductal Adenocarcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma drugs and therapies

 

Pancreatic Ductal Adenocarcinoma Pipeline Market Drivers

• Increasing pervasiveness of the disease, increasing demand of targeted therapy are some of the important factors that are fueling the Pancreatic Ductal Adenocarcinoma Market.

 

Pancreatic Ductal Adenocarcinoma Pipeline Market Barriers

• However, lack of early diagnostic markers, complicated and multifactorial nature of disease, diverse genetics and rapid metastasis and other factors are creating obstacles in the Pancreatic Ductal Adenocarcinoma Market growth.

 

Scope of Pancreatic Ductal Adenocarcinoma Pipeline Drug Insight

• Coverage: Global

• Key Pancreatic Ductal Adenocarcinoma Companies: Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, and others

• Key Pancreatic Ductal Adenocarcinoma Therapies: DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, and others

• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment: Pancreatic Ductal Adenocarcinoma current marketed and Pancreatic Ductal Adenocarcinoma emerging therapies

• Pancreatic Ductal Adenocarcinoma Market Dynamics: Pancreatic Ductal Adenocarcinoma market drivers and Pancreatic Ductal Adenocarcinoma market barriers

 

Request for Sample PDF Report for Pancreatic Ductal Adenocarcinoma Pipeline Assessment and clinical trials

 

Table of Contents

1. Pancreatic Ductal Adenocarcinoma Report Introduction

2. Pancreatic Ductal Adenocarcinoma Executive Summary

3. Pancreatic Ductal Adenocarcinoma Overview

4. Pancreatic Ductal Adenocarcinoma- Analytical Perspective In-depth Commercial Assessment

5. Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics

6. Pancreatic Ductal Adenocarcinoma Late Stage Products (Phase II/III)

7. Pancreatic Ductal Adenocarcinoma Mid Stage Products (Phase II)

8. Pancreatic Ductal Adenocarcinoma Early Stage Products (Phase I)

9. Pancreatic Ductal Adenocarcinoma Preclinical Stage Products

10. Pancreatic Ductal Adenocarcinoma Therapeutics Assessment

11. Pancreatic Ductal Adenocarcinoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pancreatic Ductal Adenocarcinoma Key Companies

14. Pancreatic Ductal Adenocarcinoma Key Products

15. Pancreatic Ductal Adenocarcinoma Unmet Needs

16 . Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers

17. Pancreatic Ductal Adenocarcinoma Future Perspectives and Conclusion

18. Pancreatic Ductal Adenocarcinoma Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Multiple Myeloma Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotech, CASI Pharma, Sorrento Therap

The Key Multiple Myeloma Companies in the market include - Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bristol-Myers Squibb and Bluebird bio, Sanofi, and others.

 

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Multiple Myeloma, offering comprehensive insights into the Multiple Myeloma revenue trends, prevalence, and treatment landscape. The report delves into key Multiple Myeloma statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Multiple Myeloma therapies. Additionally, we cover the landscape of Multiple Myeloma clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Multiple Myeloma treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Multiple Myeloma space.

 

To Know in detail about the Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Myeloma Market Forecast

 

Some of the key facts of the Multiple Myeloma Market Report:

• The Multiple Myeloma market size was valued ~USD 21,300 in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In 2023, the total multiple myeloma market in the US was approximately USD 14,300 million, with projections indicating growth by 2034.

• In the 4L+ treatment setting, approved CAR-T therapies (ABECMA and CARVYKTI) were projected to generate approximately USD 828 million in the US in 2023, with further growth anticipated as additional CAR-T therapies receive approval during the forecast period.

• In September 2025, Lupin received U.S. FDA approval for its generic Lenalidomide Capsules (2.5–25 mg), a treatment for multiple myeloma and certain cases of myelodysplastic syndromes (MDS). The product, bioequivalent to Bristol-Myers Squibb’s Revlimid®, will be manufactured at Lupin’s Pithampur facility in India.

• In August 2025, Regeneron Pharmaceuticals highlighted its PD-1 inhibitor Libtayo as the standard of care for advanced cutaneous squamous cell carcinoma (CSCC), with ongoing research in melanoma and multiple myeloma.

• In May 2025, GSK announced that the CHMP of the EMA recommended approval of Blenrep for adults with relapsed or refractory multiple myeloma. The recommendation covers use with bortezomib and dexamethasone (BVd) for patients with at least one prior therapy, and with pomalidomide and dexamethasone (BPd) for those previously treated with lenalidomide. A final decision from the European Commission is expected in Q3 2025.

• In May 2025, Johnson & Johnson announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 6-2 in favor of the benefit-risk profile of DARZALEX FASPRO® for treating high-risk smoldering multiple myeloma (HR-SMM). The FDA application for this indication was submitted in November 2024.

• In April 2025, Halozyme announced that the European Commission approved an indication extension for subcutaneous DARZALEX® (daratumumab) co-formulated with ENHANZE®. The new approval allows its use with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) in newly diagnosed multiple myeloma patients.

• In March 2025, the FDA issued its first untitled letter to Edenbridge Pharmaceuticals (now Dexcel Pharma) over a promotional panel for Hemady. Triggered by a Bad Ad complaint, the FDA flagged omitted information and weak study data. Hemady, an oral dexamethasone formulation, provides 20 mg per tablet to reduce pill burden in multiple myeloma patients.

• In February 2025, Opna Bio announced that its oral small molecule inhibitor, OPN-6602, received FDA Orphan Drug designation for multiple myeloma. OPN-6602 targets E1A-binding protein (EP300) and CREB-binding protein (CBP).

• Key Multiple Myeloma Companies: Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bristol-Myers Squibb and Bluebird bio, Sanofi, and others

• Key Multiple Myeloma Therapies: Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, CARVYKTI (ciltacabtagene autoleucel) TALVEY (talquetamab), ABECMA, SARCLISA

• The Multiple Myeloma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Myeloma pipeline products will significantly revolutionize the Multiple Myeloma market dynamics.

• In 2023, the total incidence of multiple myeloma across the 7MM was approximately 75,000 cases, with numbers expected to rise over the forecast period.

• Within the 7MM, the United States reported the highest incidence of multiple myeloma, followed by the EU4 countries and the UK.

• In 2023, within the EU4 and the UK, Germany recorded the highest number of new multiple myeloma cases, while Spain reported the lowest.

• Multiple myeloma occurs more frequently in males than females, with over 50% of cases in the United States diagnosed in men.

• Data indicates that approximately half of newly diagnosed multiple myeloma patients are not eligible for transplant, and about one-third of those who are eligible do not undergo the procedure. In 2023, the US had roughly 23,600 frontline transplant-ineligible and 9,200 transplant-eligible multiple myeloma patients.

• In terms of age-specific incidence, individuals aged 65 and above represent the largest proportion of multiple myeloma cases in the United States, accounting for over 70% of cases, followed by those aged 55–64 and 0–54 years.

 

Multiple Myeloma Overview

Multiple Myeloma is a type of blood cancer that affects plasma cells, a type of white blood cell responsible for producing antibodies. In MM, abnormal plasma cells multiply uncontrollably in the bone marrow, leading to impaired immune function, bone damage, anemia, kidney problems, and increased risk of infections. The disease is typically chronic and progresses over time, with symptoms including bone pain, fatigue, frequent infections, and high calcium levels. Treatment often involves a combination of chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, and supportive care to manage symptoms and slow disease progression.

 

Get a Free sample for the Multiple Myeloma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/multiple-myeloma-market

 

Multiple Myeloma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Multiple Myeloma Epidemiology Segmentation:

The Multiple Myeloma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Multiple Myeloma

• Prevalent Cases of Multiple Myeloma by severity

• Gender-specific Prevalence of Multiple Myeloma

• Diagnosed Cases of Episodic and Chronic Multiple Myeloma

 

Download the report to understand which factors are driving Multiple Myeloma epidemiology trends @ Multiple Myeloma Epidemiology Forecast

 

Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Myeloma market or expected to get launched during the study period. The analysis covers Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Multiple Myeloma Therapies and Key Companies

• Zevorcabtagene Autoleucel: Carsgen Therapeutics

• Descartes 08: Cartesian Therapeutics

• GC012F: Gracell Biotechnology Shanghai Co., Ltd.

• CID-103: CASI Pharmaceuticals

• STI-1492: Sorrento Therapeutics

• CARVYKTI (ciltacabtagene autoleucel): Johnson & Johnson Innovative Medicine

• TALVEY (talquetamab): Johnson & Johnson Innovative Medicine

• ABECMA: Bristol-Myers Squibb and Bluebird bio

• SARCLISA: Sanofi

 

Discover more about therapies set to grab major Multiple Myeloma market share @ Multiple Myeloma Treatment Landscape

 

Multiple Myeloma Market Drivers

• Rising global prevalence of multiple myeloma due to aging populations.

• Advances in targeted therapies, immunotherapies, and CAR-T cell treatments improving patient outcomes.

• Increasing adoption of novel combination therapies and personalized medicine approaches.

• Growing awareness and early diagnosis through improved diagnostic technologies.

• Expansion of reimbursement and healthcare infrastructure in emerging markets.

 

Multiple Myeloma Market Barriers

• High cost of innovative therapies limiting patient access, especially in developing regions.

• Complex treatment regimens leading to patient non-compliance.

• Safety and adverse effect concerns associated with long-term therapy.

• Limited availability of specialized treatment centers for advanced therapies like CAR-T.

• Regulatory hurdles and lengthy approval timelines for new drugs.

 

Scope of the Multiple Myeloma Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Multiple Myeloma Companies: Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bristol-Myers Squibb and Bluebird bio, Sanofi, and others

• Key Multiple Myeloma Therapies: Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, CARVYKTI (ciltacabtagene autoleucel) TALVEY (talquetamab), ABECMA, SARCLISA, and others

• Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies

• Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Multiple Myeloma Unmet Needs, KOL’s views, Analyst’s views, Multiple Myeloma Market Access and Reimbursement

 

To know more about Multiple Myeloma companies working in the treatment market, visit @ Multiple Myeloma Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Multiple Myeloma Market Report Introduction

2. Executive Summary for Multiple Myeloma

3. SWOT analysis of Multiple Myeloma

4. Multiple Myeloma Patient Share (%) Overview at a Glance

5. Multiple Myeloma Market Overview at a Glance

6. Multiple Myeloma Disease Background and Overview

7. Multiple Myeloma Epidemiology and Patient Population

8. Country-Specific Patient Population of Multiple Myeloma

9. Multiple Myeloma Current Treatment and Medical Practices

10. Multiple Myeloma Unmet Needs

11. Multiple Myeloma Emerging Therapies

12. Multiple Myeloma Market Outlook

13. Country-Wise Multiple Myeloma Market Analysis (2020–2034)

14. Multiple Myeloma Market Access and Reimbursement of Therapies

15. Multiple Myeloma Market Drivers

16. Multiple Myeloma Market Barriers

17. Multiple Myeloma Appendix

18. Multiple Myeloma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/